Modified oligonucleotides for telomerase inhibition

Details Modified oligonucleotides for telomerase inhibition Modified oligonucleotides for telomerase inhibition

2004-09-09

2009-02-24

Epps-Ford, Janet L (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023100, C536S024300, C536S024310, C536S024330, C536S024500

Reexamination Certificate

active

07494982

ABSTRACT:
Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.

REFERENCES:
patent: 4757141 (1988-07-01), Fung et al.
patent: 4904582 (1990-02-01), Tullis
patent: 4958013 (1990-09-01), Letsinger
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5416203 (1995-05-01), Letsinger
patent: 5420330 (1995-05-01), Brush
patent: 5563050 (1996-10-01), Peyman et al.
patent: 5763208 (1998-06-01), Bischofberger et al.
patent: 5837694 (1998-11-01), Barrett
patent: 5846723 (1998-12-01), Kim et al.
patent: 5856461 (1999-01-01), Colote et al.
patent: 5952490 (1999-09-01), Hanecak et al.
patent: 6001991 (1999-12-01), Dean et al.
patent: 6015710 (2000-01-01), Shay et al.
patent: 6153737 (2000-11-01), Manoharan et al.
patent: 6166188 (2000-12-01), Cook et al.
patent: 6221850 (2001-04-01), McKay et al.
patent: 6235886 (2001-05-01), Manoharan et al.
patent: 6265558 (2001-07-01), Cook et al.
patent: 6350853 (2002-02-01), Nielsen et al.
patent: 6395492 (2002-05-01), Manoharan et al.
patent: 6448392 (2002-09-01), Hostetler et al.
patent: 6762169 (2004-07-01), Manoharan
patent: 7067497 (2006-06-01), Hanecak et al.
patent: 2003/0138814 (2003-07-01), Gryaznov et al.
patent: 2007/0015723 (2007-01-01), Hanecak et al.
patent: 2007/0270363 (2007-11-01), Bennett et al.
patent: WO 90/10448 (1990-09-01), None
patent: WO 94/08053 (1994-04-01), None
patent: WO 96/01835 (1996-01-01), None
patent: WO 97/37691 (1997-10-01), None
patent: WO 97/38013 (1997-10-01), None
patent: WO 01/18015 (2001-03-01), None
patent: WO 2004/029277 (2004-04-01), None
C. A. Stein, Pharmacology & Therapeutics vol. 85, pp. 231-236, 2000.
Jen et al. Stem Cells, vol. 18, pp. 307-319, 2000.
Chirilia et al. Biomaterials, vol. 23, pp. 321-342, 2002.
Shea-Herbert et al. Oncogene 21, 638-642 (Jan. 18, 2002).
Schirmeister-Tichy et al. Helvetica Chimica Acta. vol. 82, 597-613, (1999).
Manoharan, M. Antisense & Nucleic Acid Drug Development. vol. 12, 103-128 (2002).
Crooke et al.,The Journal of Pharmacology and Exp. Res., 277(2):923-937 (1996).
Fiedler et al.,Langenbeck's Arch. Surg., 383:269-275 (1998).
Gerster et al.,Analytical Biochemistry, 262:177-184 (1998).
Gryaznov and Lloyd,Nucleic Acids Research, 21:5909-5915 (1993).
MacKellar et al.,Nucleic Acids Res., 20(13):3411-3417 (1992).
Manoharan, M.,Antisense and Nucleic Drug Dev., 12:103-128 (2002).
Manoharan et al.,Bioorg. Med. Chem., 4(8):1053-1060 (2002).
Mishra et al.,Biochimica et Biophysica ACTA, 1264:229-237 (1995).
Saison-Behmoaras et al.,The Embo Journal, 10(5):1111-1118 (1991).
Will et al.,Tetrahedron Letters, 33(19):2729-2732 (1992).
Asai et al.,Cancer Res., 63:3931-3939 (2003).
Nelson et al.,Nucleic Acids Research20(23):6253-6259 (1992).
Pruzan et al.,Nucleic Acids Research, 30(2):559-568 (2002).
Shea et al.,Nucleic Acids Research, 18(13):3777-3783 (1990).
Office Action mailed Aug. 29, 2008, in U.S. Appl. No. 10/255,535, filed Sep. 25, 2002.
Herbert et al., “Inhibition of human telomerase in immortal human cells lead to progressive telomere shortening and cell death,”Proc. Natl. Acad. Sci. USA 96(25):14276-81 (Dec. 7, 1999).
Non-final Office Action dated Jan. 8, 2008, in U.S. Appl. No. 10/255,535.
Final Office Action dated May 15, 2007 in U.S. Appl. No. 10/255,535.
Non-final Office Action dated Sep. 8, 2006, in U.S. Appl. No. 10/255,535.

Affiliated with

Also associated with

Rating

Modified oligonucleotides for telomerase inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified oligonucleotides for telomerase inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified oligonucleotides for telomerase inhibition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4083450